Mark Neumann Intra Cellular Therapies, Inc. (ITCI) insider trading activity

Mark Neumann is EVP, Chief Commercial Officer of Intra-Cellular Therapies, Inc.. Currently has a direct ownership of 0 shares of ITCI, which is worth approximately $0. The most recent transaction as insider was on Mar 10, 2023, when has been sold 8,550 shares (Common Stock) at a price of $43.12 per share, resulting in proceeds of $368,676. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

Mark Neumann Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 10 2023	SELL Open market or private sale	$368,676 $43.12 p/Share	8,550 Reduced 12.97%	57,357 Common Stock
Mar 10 2023	BUY Exercise of conversion of derivative security	-	7,344 Added 10.19%	64,701 Common Stock
Mar 09 2023	BUY Grant, award, or other acquisition	-	16,708 Added 20.22%	65,907 Common Stock
Mar 01 2023	SELL Open market or private sale	$362,122 $50.01 p/Share	7,241 Reduced 12.83%	49,199 Common Stock
Feb 24 2023	SELL Open market or private sale	$190,647 $47.12 p/Share	4,046 Reduced 6.69%	56,440 Common Stock
Feb 23 2023	BUY Exercise of conversion of derivative security	-	7,906 Added 11.56%	60,486 Common Stock
Feb 21 2023	SELL Open market or private sale	$185,622 $47.62 p/Share	3,898 Reduced 6.9%	52,580 Common Stock
Feb 18 2023	BUY Exercise of conversion of derivative security	-	11,139 Added 16.47%	56,478 Common Stock
Apr 08 2022	SELL Open market or private sale	$5,558,221 $64.37 p/Share	86,348 Reduced 65.57%	45,339 Common Stock
Apr 08 2022	BUY Exercise of conversion of derivative security	$1,099,210 $12.73 p/Share	86,348 Added 39.6%	131,687 Common Stock
Feb 24 2022	SELL Open market or private sale	$411,903 $52.1 p/Share	7,906 Reduced 14.85%	45,339 Common Stock
Feb 23 2022	BUY Exercise of conversion of derivative security	-	7,906 Added 12.93%	53,245 Common Stock
Feb 22 2022	SELL Open market or private sale	$615,096 $55.22 p/Share	11,139 Reduced 19.72%	45,339 Common Stock
Feb 18 2022	BUY Exercise of conversion of derivative security	-	11,139 Added 16.47%	56,478 Common Stock
Jan 10 2022	SELL Open market or private sale	$856,354 $40.88 p/Share	20,948 Reduced 31.6%	45,339 Common Stock
Jan 08 2022	BUY Exercise of conversion of derivative security	-	20,948 Added 24.01%	66,287 Common Stock
Oct 18 2021	SELL Open market or private sale	$539,937 $40.15 p/Share	13,448 Reduced 22.88%	45,339 Common Stock
Oct 15 2021	BUY Exercise of conversion of derivative security	-	13,448 Added 18.62%	58,787 Common Stock
Feb 19 2021	SELL Open market or private sale	$202,591 $39.08 p/Share	5,184 Reduced 10.26%	45,339 Common Stock
Feb 18 2021	BUY Exercise of conversion of derivative security	-	11,139 Added 18.06%	50,523 Common Stock
Jan 11 2021	SELL Open market or private sale	$310,082 $32.02 p/Share	9,684 Reduced 19.74%	39,384 Common Stock
Jan 08 2021	BUY Exercise of conversion of derivative security	-	20,948 Added 29.92%	49,068 Common Stock
Oct 16 2020	SELL Open market or private sale	$182,026 $26.8 p/Share	6,792 Reduced 19.45%	28,120 Common Stock
Oct 15 2020	BUY Exercise of conversion of derivative security	-	13,448 Added 27.81%	34,912 Common Stock

Mark Neumann

EVP, Chief Commercial Officer

New York, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ITCI shares.

Notify only if

Value

Insider Trading

Get notified when an Intra Cellular Therapies, Inc. insider buys or sells ITCI shares.

Notify only if

Operation

Value

Type

News

Receive news related to Intra-Cellular Therapies, Inc.

Track Activities on ITCI

Account